Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by RepliCel Life Sciences, Inc.

RepliCel’s Manufacturing Inspected by Japan’s PMDA
From RepliCel Life Sciences, Inc.
Via AccessWire
Tickers REPCF TSX-V:RP
CORRECTION: Independent Laboratory Test Results Confirm Value of DermaPreciseTM Injection Consistency in Clinical Simulation Testing
From RepliCel Life Sciences, Inc.
Via AccessWire
Tickers REPCF TSX-V:RP
Independent Laboratory Test Results Confirm Value of DermaPrecise (TM) Injection Consistency in Clinical Simulation Testing
From RepliCel Life Sciences, Inc.
Via AccessWire
Tickers REPCF TSX-V:RP
RepliCel Announces Material Patent Milestones
From RepliCel Life Sciences, Inc.
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property
Tickers REPCF TSX-V:RP
RepliCel Closed Final Tranche of Strategic Investment Commitment
From RepliCel Life Sciences, Inc.
Via AccessWire
Tickers REPCF TSX-V:RP
RepliCel Terminates License Agreement with Shiseido
From RepliCel Life Sciences, Inc.
Via AccessWire
Tickers REPCF TSX-V:RP
RepliCel Ships DermaPrecise(TM) Injector Prototypes and Consumables to Independent Laboratory for Clinical Simulation Testing
From RepliCel Life Sciences, Inc.
Via AccessWire
Tickers REPCF TSX-V:RP
RepliCel’s Clinical Advisory Team Delivers Skin Rejuvenation Clinical Study Synopsis to its Japanese Regulatory and Clinical Study Management Team
From RepliCel Life Sciences, Inc.
Via AccessWire
Tickers REPCF TSX-V:RP
RepliCel Announces DermaPrecise Trademark for Dermal Injector Product Line
From RepliCel Life Sciences, Inc.
Via AccessWire
Tickers REPCF TSX-V:RP
RepliCel Announces Dermal Injector Update
From RepliCel Life Sciences, Inc.
Via AccessWire
Tickers REPCF TSX-V:RP
RepliCel Files Notice of Arbitration against Shiseido Company to Resolve its License Agreement Dispute Regarding its Androgenetic Alopecia Cell Therapy
From RepliCel Life Sciences, Inc.
Via AccessWire
Tickers REPCF TSX-V:RP
RepliCel Life Sciences Appoints One of Japan's Foremost Regenerative Medicine Industry Business Leaders as Strategic Advisor
From RepliCel Life Sciences, Inc.
Via AccessWire
Topics Economy
Exposures Economy
Tickers REPCF TSX-V:RP
RepliCel and University of Victoria Collaboration Leads to Bioengineering Innovations, Funding, and Patents
From RepliCel Life Sciences, Inc.
Via AccessWire
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Tickers REPCF TSX-V:RP
RepliCel Applies for Manufacturing Approval for Its Collagen and Tissue Regeneration Cell Therapies
From RepliCel Life Sciences, Inc.
Via AccessWire
Tickers REPCF TSX-V:RP
RepliCel Adds Independent Director
From RepliCel Life Sciences, Inc.
Via AccessWire
Topics Artificial Intelligence
Exposures Artificial Intelligence
Tickers REPCF TSX-V:RP
RepliCel Launches Testing of Dermal Injector Units
From RepliCel Life Sciences, Inc.
Via AccessWire
Tickers REPCF TSX-V:RP
RepliCel Launches Preparations for Second Skin Rejuvenation and Tendon Regeneration Clinical Studies
From RepliCel Life Sciences, Inc.
Via AccessWire
Tickers REPCF TSX-V:RP
RepliCel Announces Appointment of Leading Dermatologist in Japan as Clinical Advisor
From RepliCel Life Sciences, Inc.
Via AccessWire
Tickers REPCF TSX-V:RP
RepliCel Launches the Next Stage of a Research Project with the University of British Columbia to Build World-Class Hair Follicle Cell Data Map
From RepliCel Life Sciences, Inc.
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property
Tickers REPCF TSX-V:RP
RepliCel Announces Record Year in Patents Granted
From RepliCel Life Sciences, Inc.
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property
Tickers REPCF TSX-V:RP
RepliCel Announces Appointment of Leading Sports Medicine Expert as Orthopedics Clinical Advisor (Japan)
From RepliCel Life Sciences, Inc.
Via AccessWire
Tickers REPCF TSX-V:RP
RepliCel Closes Second Tranche of Strategic Investment Commitment
From RepliCel Life Sciences, Inc.
Via AccessWire
Tickers REPCF TSX-V:RP
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.